At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
RAD001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
In Brief
A Phase 2 clinical trial evaluating RAD001 for Thyroid Cancer. Completed, enrolled 50 participants across 4 sites.
Detailed Summary
Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise. This trial seeks to expand treatment options for this disease with a new, oral drug called RAD001. It is an inhibitor of the mTOR pathway and has shown activity in neuroendocrine cancers of the gastrointestinal tract and has been approved for the treatment of metastatic renal cell cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesUnited States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionFeb 2020
TodayJul 2026
First PostedJul 10, 2009
Enrollment StartJul 1, 2009
Primary CompletionFeb 27, 2020
TodayJul 2, 2026
Enrollment to primary: 10.7 yearsPosted 17.0 years ago
Interventions
RAD001drug